LKFT Lakefront Biotherapeutics
Financings ·
Repurchases run no later than December 31, 2026. The company expects year-end 2026 cash and financial investments of EUR 1.975 billion to EUR 2.050 billion, including the buyback.
Gilead agreed to buy Ouro Medicines for $1,675 million in cash plus up to $500 million in milestones. Galapagos said it would pay 50% of the upfront cost under proposed terms, and no agreement between the two companies had been signed.
The company lowered its expected cell therapy restructuring cash costs to €125 to €175 million. It expects to be a lean organization of about 35-40 employees by the end of 2026.
Our latest story on this, dated Aug 12, 2026: "Lakefront Biotherapeutics reports 241,904 shares bought back under EUR 50 million program". The story links the filing or release it is based on. Read the story.
Lakefront Biotherapeutics trades under the ticker LKFT on EURONEXT.
Lakefront Biotherapeutics is listed on EURONEXT. Our directory also records these other listings: BMFBOVESPA:LKFT34; DUS:GXE; EUROTLX:4LKFT; FWB:GXE; GETTEX:GXE; HAM:GXE; HAN:GXE; LS:A0EAT9; LSIN:0JXZ; MUN:GXE; NASDAQ:LKFT; SWB:GXE; TRADEGATE:GXE; VIE:LKFT; XETR:GXE.
The SEC Central Index Key (CIK) for Lakefront Biotherapeutics is 1421876. Its filings are on SEC EDGAR.
65,897,071 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-26.
Our directory records Lakefront Biotherapeutics under Belgium.
Our directory classifies Lakefront Biotherapeutics as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lakefront Biotherapeutics is BE0003818359.
aibio.space lists Lakefront Biotherapeutics among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as C9.
Our latest story on Lakefront Biotherapeutics, dated Aug 12, 2026: "Lakefront Biotherapeutics reports 241,904 shares bought back under EUR 50 million program". Repurchases run no later than December 31, 2026. The company expects year-end 2026 cash and financial investments of EUR 1.975 billion to EUR 2.050 billion, including the buyback. Source.
Our latest financing story, dated Aug 12, 2026: "Lakefront Biotherapeutics reports 241,904 shares bought back under EUR 50 million program". Repurchases run no later than December 31, 2026. The company expects year-end 2026 cash and financial investments of EUR 1.975 billion to EUR 2.050 billion, including the buyback. Source.
From our story of Mar 24, 2026: Gilead agreed to buy Ouro Medicines for $1,675 million in cash plus up to $500 million in milestones. Source.
Our latest distress story, dated Feb 23, 2026: "Galapagos (now Lakefront Biotherapeutics) lowers wind-down cost estimate, holds €3.0 billion". The company lowered its expected cell therapy restructuring cash costs to €125 to €175 million. It expects to be a lean organization of about 35-40 employees by the end of 2026. Source.
Our latest merger story, dated Mar 24, 2026: "Galapagos (now Lakefront Biotherapeutics) in advanced talks with Gilead on Ouro program". Gilead agreed to buy Ouro Medicines for $1,675 million in cash plus up to $500 million in milestones. Galapagos said it would pay 50% of the upfront cost under proposed terms, and no agreement between the two companies had been signed. Source.
Announced a share repurchase program. SEC Form 6-K. Source
Announced a share repurchase program. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio